ASRT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

6.20M

-80.74%

-0.207

+88.64%

14.70M

-44.52%

-0.070

-50%

28.40M

-2.81%

-0.025

-85.29%

Estimates Revision

The market is revising Upward the revenue expectations for Assertio Holdings, Inc. (ASRT) for FY2025, with the revenue forecasts being adjusted by 0.39% over the past three months. During the same period, the stock price has changed by -27.25%.

Revenue Estimates for FY2025

Revise Upward

+0.39%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.6%

In Past 3 Month

Stock Price

Go Down

-27.25%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ASRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASRT is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

H.C. Wainwright

Raghuram Selvaraju

upgrade

$3 -> $35

2026-01-05

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$3 -> $35

2026-01-05

upgrade

Reason

H.C. Wainwright analyst Raghuram Selvaraju adjusted the firm's price target on Assertio to $35 from $3 and keeps a Buy rating on the shares following the the one-for-15 reverse split.

H.C. Wainwright

Buy

downgrade

2025-08-12

Reason

H.C. Wainwright

Price Target

2025-08-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Assertio to $3 from $3.50 and keeps a Buy rating on the shares. The company reported a sales beat and earnings miss, the analyst tells investors in a research note.

Alliance Global Partners

Buy

maintain

2025-05-13

Reason

Alliance Global Partners

Price Target

2025-05-13

maintain

Buy

Reason

Alliance Global Partners lowered the firm's price target on Assertio to $1.50 from $1.75 and keeps a Buy rating on the shares following the Q1 report. The company's Q1 revenue was below forecast driven largely by Rolvedon, the analyst tells investors in a research note. Now that Assertio appears to have cleaned up the opioid overhang litigation, the share price should start tracking Rolvedon, for better or worse, contends Alliance Global .

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$4 → $3.5

2025-03-19

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$4 → $3.5

2025-03-19

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Assertio Holdings Inc (ASRT.O) is -1.86, compared to its 5-year average forward P/E of 6.93. For a more detailed relative valuation and DCF analysis to assess Assertio Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

6.93

Current PE

-1.86

Overvalued PE

90.95

Undervalued PE

-77.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

2.07

Current EV/EBITDA

-1.63

Overvalued EV/EBITDA

4.38

Undervalued EV/EBITDA

-0.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.96

Current PS

0.75

Overvalued PS

1.38

Undervalued PS

0.55

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ASRT News & Events

Events Timeline

No data

News

9.0

01-09Businesswire

PinnedAssertio Reports Positive Clinical Trial Results for Rolvedon with Same-Day Dosing

9.0

01-09Newsfilter

Assertio Reports Positive Results for Same-Day Dosing of Rolvedon in Clinical Trial

2.0

2025-12-22SeekingAlpha

Assertio Holdings declares a 1-for-15 reverse stock split.

People Also Watch

Frequently Asked Questions

What is Assertio Holdings Inc (ASRT) stock price today?

The current price of ASRT is 9.19 USD — it has decreased -1.29 % in the last trading day.

What is Assertio Holdings Inc (ASRT)'s business?

Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

What is the price predicton of ASRT Stock?

What is Assertio Holdings Inc (ASRT)'s revenue for the last quarter?

Assertio Holdings Inc revenue for the last quarter amounts to 49.46M USD, increased 69.36 % YoY.

What is Assertio Holdings Inc (ASRT)'s earnings per share (EPS) for the last quarter?

Assertio Holdings Inc. EPS for the last quarter amounts to 0.11 USD, decreased -466.67 % YoY.

What changes have occurred in the market's expectations for Assertio Holdings Inc (ASRT)'s fundamentals?

How many employees does Assertio Holdings Inc (ASRT). have?

Assertio Holdings Inc (ASRT) has 58 emplpoyees as of January 11 2026.

What is Assertio Holdings Inc (ASRT) market cap?

Today ASRT has the market capitalization of 58.97M USD.